European Commission approves Amgen’s IMLYGIC as first oncolytic immunotherapy in Europe
IMLYGIC is approved in the European Union specifically for early stage metastatic patients
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Oncology early stage metastic patients herpes simplex type 1 virus IMLYGIC immunotherapy Latest News melanoma Source Type: news
More News: Cancer & Oncology | Cold Sores | Drugs & Pharmacology | Herpes | Immunotherapy | Melanoma | Skin Cancer